Výsledky vyhledávání - "M. N. Reaume"

Progression-free survival as a clinical trial endpoint in advanced renal cell carcinoma

Autor: S J, Hotte, G A, Bjarnason, D Y C, Heng, M A S, Jewett, A, Kapoor, C, Kollmannsberger, J, Maroun, L A, Mayhew, S, North, M N, Reaume, J D, Ruether, D, Soulieres, P M, Venner, E W, Winquist, L, Wood, J H E, Yong, F, Saad

Publikováno v: Current oncology (Toronto, Ont.). 18

Traditionally, overall survival (os) has been considered the "gold standard" for evaluating new systemic oncologic therapies, because death is easy to define, is easily compared across disease sites, and is not subject to investigator bias. However,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::66ff2bc6850d99debd38523297473eb1
https://pubmed.ncbi.nlm.nih.gov/21969807

Zobrazit plný text záznamu

Determining knowledge transfer gaps in the life cycle of evidence for chemotherapy in non-small cell lung cancer (NSCLC) through cumulative meta-analysis

Autor: J. McGowan, M. Nurbhai, M. N. Reaume, Ian D. Graham, P.L. Moja, W K Evans, Keith O'Rourke, J. M. Grimshaw

Publikováno v: Journal of Clinical Oncology. 25:6555-6555

6555 Background: The uptake of research findings into practice is often delayed (Antman et al. JAMA 1992). We investigated the relative role of evidence in determining clinical recommendations and practice for NSCLC. Novel chemotherapy agents (NCA) a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::43b63bafee68ec1e22fe4213aba9fa18
https://doi.org/10.1200/jco.2007.25.18_suppl.6555

Zobrazit plný text záznamu

Randomized phase II trial of cisplatin/gemcitabine with or without LY293111, a multiple eicosonaid pathway modulator, in patients with chemotherapy naïve advanced non-small cell lung carcinoma

Autor: Y. W. Oh, Pasi A. Jänne, J. von Pawel, Nathan Enas, M. Gottfried, Leslie Brail, M. N. Reaume, A. Sykes, T. Kaukel, L. Paz-Ares Rodriguez

Publikováno v: Journal of Clinical Oncology. 24:7024-7024

7024 Background: The eicosanoid pathway is altered in NSCLC. Pharmacological activators of peroxisome proliferator-activated receptor-gamma (PPARγ) have been shown to inhibit lung tumors in vitro. LY293111 inhibits the eicosanoid pathway, is a PPAR�

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d728abd60f76f85ce1a808acd48da3e4
https://doi.org/10.1200/jco.2006.24.18_suppl.7024

Zobrazit plný text záznamu

Clinical evidence of efficacy of the temozolomide/gemcitabine combination against non-small cell (nsclc) and small cell (sclc) lung cancers

Autor: D. A. Bedard, David J. Stewart, Scott A. Laurie, M. N. Reaume, D. L. Cutler, Stan Z. Gertler, R. Goel, M. C. Cripps, A. Rodgers, Glenwood D. Goss

Publikováno v: Journal of Clinical Oncology. 23:7338-7338

7338 Background: A phase I study of (TZ)/(GC) combination has been completed, and the results previously presented at ESMO (Ann Oncol 15(3):198, 2004). Here, we report on this regimen’s activity in...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::6eb64a4959ea8c10f354f56e7ef49aba
https://doi.org/10.1200/jco.2005.23.16_suppl.7338

Zobrazit plný text záznamu

A phase I safety and PK study of the novel vascular targeting agent (VTA), Exherin, in patients with refractory solid tumors stratified according to N-cadherin expression

Autor: R. Goel, David J. Stewart, Derek J. Jonker, Glenwood D. Goss, L. Avruch, W. P. Peters, T. A. Spencer, M. N. Reaume, Susan Dent

Publikováno v: Journal of Clinical Oncology. 22:3078-3078

3078 Background: Exherin is a novel angiolytic VTA which specifically targets existing tumor vessels. Exherin is a cyclic pentapeptide (CHAVC) which competitively inhibits N-cadherin mediated endothelial cell, pericyte and tumor cell binding. Exherin

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::42dac4ffab0453aa16c9f0728922467d
https://doi.org/10.1200/jco.2004.22.90140.3078

Zobrazit plný text záznamu

Genitourinary (GU) small cell carcinoma (SCC): A retrospective review of treatment and survival patterns at the Ottawa Regional Cancer Center (ORCC)

Autor: M. N. Reaume, Simone Dahrouge, Shawn Malone, Timothy R. Asmis

Publikováno v: Journal of Clinical Oncology. 22:4545-4545

4545 Background: SCC of the bladder (SCCB), prostate (SCCP), and kidney (SCCK) remains a therapeutic challenge. Much debate exists in the literature about the ideal course of therapy. Methods: All ...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::430cfe95444f08dc467574dcec84be56
https://doi.org/10.1200/jco.2004.22.90140.4545

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání